Mesenchymal Stem Cells for Cardiac Therapy: Practical Challenges and Potential Mechanisms

Stem Cell Reviews and Reports

Volumn 9, Issue 3, 2013, Pages 254-265

  Cashman, Timothy J ^a   Gouon Evans, Valerie ^a   Costa, Kevin D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac repair; Cellular therapy; Differentiation; Marrow stromal cell; Molecular markers; Paracrine signaling; Reprogramming; Tissue engineering

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSDIFFERENTIATION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PARACRINE SIGNALING; TISSUE ENGINEERING;

CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSDIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; TISSUE ENGINEERING;

EID: 84878962431     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-012-9375-6     Document Type: Article

References (60)

1. Pittenger, M. F., Mackay, A. M., Beck, S. C., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
2. Song, L., & Tuan, R. S. (2004). Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. The FASEB Journal, 18, 980-982.
3. Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418, 41-49.
4. Hare, J. M., Traverse, J. H., Henry, T. D., et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54, 2277-2286.
5. Li, Y., Yao, Y., Sheng, Z., Yang, Y., & Ma, G. (2011). Dual-modal tracking of transplanted mesenchymal stem cells after myocardial infarction. International Journal of Nanomedicine, 6, 815-823.
6. Williams, A. R., Trachtenberg, B., Velazquez, D. L., et al. (2011). Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circulation Research, 108, 792-796.
7. Quevedo, H. C., Hatzistergos, K. E., Oskouei, B. N., et al. (2009). Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proceedings of the National Academy of Sciences of the United States of America, 106, 14022-14027.
8. Amado, L. C., Saliaris, A. P., Schuleri, K. H., et al. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 102, 11474-11479.
9. Miyahara, Y., Nagaya, N., Kataoka, M., et al. (2006). Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nature Medicine, 12, 459-465.
10. Koninckx, R., Hensen, K., Daniëls, A., et al. (2009). Human bone marrow stem cells co-cultured with neonatal rat cardiomyocytes display limited cardiomyogenic plasticity. Cytotherapy, 11, 778-792.
11. Ranganath, S. H., Levy, O., Inamdar, M. S., & Karp, J. M. (2012). Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell, 10, 244-258.
12. Friis, T., Haack-Sørensen, M., Mathiasen, A. B., et al. (2011). Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scandinavian Cardiovascular Journal, 45, 161-168.
13. Penn, M. S., Ellis, S., Gandhi, S., et al. (2012). Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circulation Research, 110, 304-311.
14. Lunde, K., Solheim, S., Aakhus, S., et al. (2006). Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. The New England Journal of Medicine, 355, 1199-1209.
15. Wollert, K. C., Meyer, G. P., Lotz, J., et al. (2004). Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet, 364, 141-148.
16. Schaefer, A., Zwadlo, C., Fuchs, M., et al. (2010). Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial-an echocardiographic study. European Journal of Echocardiography, 11, 165-171.
17. Meyer, G. P., Wollert, K. C., Lotz, J., et al. (2009). Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. European Heart Journal, 30, 2978-2984.
18. Meyer, G. P., Wollert, K. C., Lotz, J., et al. (2006). Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation, 113, 1287-1294.
19. Dai, W., Hale, S. L., Martin, B. J., et al. (2005). Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation, 112, 214-223.
20. Wen, Y., Meng, L., Xie, J., & Ouyang, J. (2011). Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis. Expert Opinion on Biological Therapy, 11, 559-567.
21. Dominici, M., Le Blanc, K., Mueller, I., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8, 315-317.
22. Acquistapace, A., Bru, T., Lesault, P.-F., et al. (2011). Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer. Stem Cells, 29, 812-824.
23. Gaebel, R., Furlani, D., Sorg, H., et al. (2011). Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PloS One, 6, e15652.
24. Bayes-Genis, A., Soler-Botija, C., Farré, J., et al. (2010). Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents. Journal of Molecular and Cellular Cardiology, 49, 771-780.
25. Zhao, Z., Chen, Z., Zhao, X., et al. (2011). Sphingosine-1-phosphate promotes the differentiation of human umbilical cord mesenchymal stem cells into cardiomyocytes under the designated culturing conditions. Journal of Biomedical Science, 18, 37.
26. Zvaifler, N. J., Marinova-Mutafchieva, L., Adams, G., et al. (2000). Mesenchymal precursor cells in the blood of normal individuals. Arthritis Research, 2, 477-488.
27. Kurth, T. B., Dell'accio, F., Crouch, V., Augello, A., Sharpe, P. T., & De Bari, C. (2011). Functional mesenchymal stem cell niches in adult mouse knee joint synovium in vivo. Arthritis and Rheumatism, 63, 1289-1300.
28. Tsuji, H., Miyoshi, S., Ikegami, Y., et al. (2010). Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circulation Research, 106, 1613-1623.
29. Sabatini, F., Petecchia, L., Tavian, M., Jodon de Villeroché, V., Rossi, G. A., & Brouty-Boyé, D. (2005). Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities. Laboratory Investigation, 85, 962-971.
30. Kawada, H., Fujita, J., Kinjo, K., et al. (2004). Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood, 104, 3581-3587.
31. Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood, 103, 1662-1668.
32. Bonios, M., Terrovitis, J., Chang, C. Y., et al. (2011). Myocardial substrate and route of administration determine acute cardiac retention and lung bio-distribution of cardiosphere-derived cells. Journal of Nuclear Cardiology, 18, 443-450.
33. Dib, N., Khawaja, H., Varner, S., McCarthy, M., & Campbell, A. (2011). Cell therapy for cardiovascular disease: a comparison of methods of delivery. Journal of Cardiovascular Translational Research, 4, 177-181.
34. Wei, F., Wang, T., Liu, J., Du, Y., & Ma, A. (2011). The subpopulation of mesenchymal stem cells that differentiate toward cardiomyocytes is cardiac progenitor cells. Experimental Cell Research, 317, 2661-2670.
35. Hatzistergos, K. E., Quevedo, H., Oskouei, B. N., et al. (2010). Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circulation Research, 107, 913-922.
36. Numasawa, Y., Kimura, T., Miyoshi, S., et al. (2011). Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis. Stem Cells, 29, 1405-1414.
37. Siegel. G., Krause, P., Wöhrle, S., et al. (2012). Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells and Development, -not available-, ahead of print.
38. Sassoli, C., Pini, A., Mazzanti, B., et al. (2011). Mesenchymal stromal cells affect cardiomyocyte growth through juxtacrine Notch-1/Jagged-1 signaling and paracrine mechanisms: clues for cardiac regeneration. Journal of Molecular and Cellular Cardiology, 51, 399-408.
39. Boni, A., Urbanek, K., Nascimbene, A., et al. (2008). Notch1 regulates the fate of cardiac progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 105, 15529-15534.
40. Abarbanell, A. M., Wang, Y., Herrmann, J. L., et al. (2010). Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury. American Journal of Physiology: Heart and Circulatory Physiology, 298, H1529-36.
41. Varoga, D., Paulsen, F., Mentlein, R., et al. (2006). TLR-2-mediated induction of vascular endothelial growth factor (VEGF) in cartilage in septic joint disease. Journal of Pathology, 210, 315-324.
42. Williams, A. R., & Hare, J. M. (2011). Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circulation Research, 109, 923-940.
43. Xu, H., Yang, Y.-J., Qian, H.-Y., Tang, Y.-D., Wang, H., & Zhang, Q. (2011). Rosuvastatin treatment activates JAK-STAT Pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circulation Journal, 75, 1476-1485.
44. Loffredo, F. S., Steinhauser, M. L., Gannon, J., & Lee, R. T. (2011). Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell, 8, 389-398.
45. Zisa, D., Shabbir, A., Suzuki, G., & Lee, T. (2009). Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. Biochemical and Biophysical Research Communications, 390, 834-838.
46. Valiunas, V., Doronin, S., Valiuniene, L., et al. (2004). Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. The Journal of Physiology, 555, 617-626.
47. Mills, W. R., Mal, N., Kiedrowski, M. J., et al. (2007). Stem cell therapy enhances electrical viability in myocardial infarction. Journal of Molecular and Cellular Cardiology, 42, 304-314.
48. Serrao, G. S., Turnbull, I. C., Ancukiewicz, D., et al. (2012). Myocyte-Depleted Engineered Cardiac Tissue Support Therapeutic Potential of Mesenchymal Stem Cells. Tissue Engineering Part A, doi: 10. 1089/ten. TEA. 2011. 0278.
49. Chang, M. G., Tung, L., Sekar, R. B., et al. (2006). Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation, 113, 1832-1841.
50. Costa, A. R., Panda, N. C., Yong, S., et al. (2012). Optical mapping of cryoinjured rat myocardium grafted with mesenchymal stem cells. American Journal of Physiology: Heart and Circulatory Physiology, 302, H270-7.
51. Ramkisoensing, A. A., Pijnappels, D. A., Askar, S. F. A., et al. (2011). Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts. PloS One, 6, e24164.
52. Hwang, N. S., Kim, M. S., Sampattavanich, S., Baek, J. H., Zhang, Z., & Elisseeff, J. (2006). Effects of three-dimensional culture and growth factors on the chondrogenic differentiation of murine embryonic stem cells. Stem Cells, 24, 284-291.
53. Engler, A. J., Sen, S., Sweeney, H. L., & Discher, D. E. (2006). Matrix elasticity directs stem cell lineage specification. Cell, 126, 677-689.
54. Engler, A. J., Carag-Krieger, C., Johnson, C. P., et al. (2008). Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating. Journal of Cell Science, 121, 3794-3802.
55. Jacot, J. G., McCulloch, A. D., & Omens, J. H. (2008). Substrate stiffness affects the functional maturation of neonatal rat ventricular myocytes. Biophysical Journal, 95, 3479-3487.
56. Domian, I. J., Chiravuri, M., van der Meer, P., et al. (2009). Generation of functional ventricular heart muscle from mouse ventricular progenitor cells. Science, 326, 426-429.
57. Tulloch, N. L., Muskheli, V., Razumova, M. V., et al. (2011). Growth of engineered human myocardium with mechanical loading and vascular coculture. Circulation Research, 109, 47-59.
58. Schaaf, S., Shibamiya, A., Mewe, M., et al. (2011). Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PloS One, 6, e26397.
59. Chen, C.-H., Wei, H.-J., Lin, W.-W., et al. (2008). Porous tissue grafts sandwiched with multilayered mesenchymal stromal cell sheets induce tissue regeneration for cardiac repair. Cardiovascular Research, 80, 88-95.
60. Simpson, D. L., Boyd, N. L., Kaushal, S., Stice, S. L., & Dudley, S. C. (2012). Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair. Biotechnology and Bioengineering, 109, 274-283.